This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Mar 2012

Islet Sciences Announces Closing of DiaKine Acquisition

Islet Sciences has announced the closing of the acquisition of DiaKine Therapeutics.

Islet Sciences, Inc. has announced the closing of the acquisition of DiaKine Therapeutics, Inc. which is now the Company's wholly owned subsidiary.


John Steel, Chairman and CEO of Islet Sciences stated, "We are pleased to announce the closing of this acquisition and look forward to executing on the combined company's synergistic market opportunity in the diabetes space. Our approach to the treatment of diabetes in addition to other inflammatory diseases and autoimmune disorders represents a very large market. DiaKine's drugs may benefit people with type 1 and type 2 diabetes that has a total addressable market of approximately $13 billion. We believe the DiaKine acquisition positions the Company to capitalize on the growing opportunities in this field."


As previously reported in

Related News